Pharming Group Notice of 9M Results
Financial updates
2021
Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST®
Clinical trialsPharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the 7-point WHO ordinal scale on Day 7.
Pharming Group reports financial results for the first half of 2021
Financial updatesRecovery continued into Q2 2021 as patient enrollment and product demand increases
Sign up now: Pharming’s Half Year Financial Results Webinar
WebinarsPharming’s CEO Sijmen de Vries and CFO Jeroen Wakkerman look back at the first half of 2021 and the recently published full year financial results.
Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa
Operational updates
Drs. Jakob (Jaap) Blaak
Other updatesWe are deeply saddened to announce the passing of our former Chairman Drs. Jakob (Jaap) Blaak.
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema
Operational updates
Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome
Clinical trials
Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer
Operational updates
Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain
Operational updates